Drug company Catalyst Biosciences, backed by Johnson & Johnson Development Corporation, raises $13.4m in its latest round. The company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation.

US-based Catalyst Biosciences raised $13.4m in funding in September as part of a planned $18.6m round, according to a filing with the Securities and Exchange Commission. 

Catalyst is backed by US-based healthcare company Johnson & Johnson Development Corporation and return backers Sofinnova Ventures, Burrill & Company, Morgenthaler Ventures, HealthCare Ventures, and Essex Woodlands Health Ventures.

Catalyst Biosciences is a developer of next generation biopharmaceuticals that target proteins underlying diseases.

This latest round of funds brings the total raised…